Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biomarin Pharmaceuticals
(NQ:
BMRN
)
70.58
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biomarin Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Why BioMarin Shares Are Plunging Today?
March 06, 2023
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) shares are falling in reaction to positive data from BridgeBio Pharma Inc's (NASDAQ: BBIO) dwarfism drug, heating the competition.
Via
Benzinga
BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study
March 06, 2023
The company is testing a drug for children with achondroplasia, a cause of dwarfism.
Via
Investor's Business Daily
Kala Pharmaceuticals Stock Showing Rising Market Leadership; Earns 83 RS Rating
March 03, 2023
On Friday, Kala Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 83, up from 67 a day earlier.
Via
Investor's Business Daily
uniQure Stock Trying To Close In On Key Technical Measure
February 28, 2023
uniQure stock had its Relative Strength Rating upgraded to 79 Tuesday -- a nice improvement, but still shy of the 80-plus desired score.
Via
Investor's Business Daily
BioMarin Hints Probable Delay For US Approval For Roctavian, But Analyst Convinced For Transformative 2023
February 28, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 22, 2023
February 22, 2023
Via
Benzinga
BioMarin Valuation Fair, But Expectations From Hemophilia Therapy Too High, Says Analyst
January 30, 2023
Via
Benzinga
Earnings Scheduled For February 27, 2023
February 27, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million.
Via
Benzinga
Preview: Biomarin Pharmaceutical's Earnings
February 24, 2023
Via
Benzinga
Analyst Ratings for Biomarin Pharmaceutical
February 22, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023
February 21, 2023
Via
Benzinga
3 Prime Healthcare Takeover Targets
February 14, 2023
These three companies are attractive targets for their potential.
Via
The Motley Fool
Moderna Stock Getting Closer To Key Technical Benchmark
February 10, 2023
On Friday, biotech Moderna stock received an upgrade to its Relative Strength (RS) Rating, to 72 from 69 a day earlier.
Via
Investor's Business Daily
What 5 Analyst Ratings Have To Say About Biomarin Pharmaceutical
January 30, 2023
Via
Benzinga
6 Analysts Have This to Say About Biomarin Pharmaceutical
January 11, 2023
Via
Benzinga
2 Top Biotech Stocks Defying the Bear Market
January 10, 2023
Some stocks are hitting new highs.
Via
The Motley Fool
Expert Ratings for Biomarin Pharmaceutical
November 29, 2022
Via
Benzinga
BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results
February 03, 2023
Chronic lumbar disc disease (cLDD) is a debilitating condition affecting millions of people worldwide. It is characterized by back pain, stiffness, and restricted movement due to damage to the bony...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
January 30, 2023
Via
Benzinga
3 Drug Stocks With Promising Pipelines for 2023
January 23, 2023
These 3 drug stocks with promising pipelines are in position to reward investors in 2023 due to multiple factors.
Via
InvestorPlace
Cramer Is Holding This Biotech Stock
January 12, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended holding Biomarin Pharmaceutical Inc (NASDAQ: BMRN).
Via
Benzinga
Vertex Pharmaceuticals Stock Sees Rising Relative Strength
January 11, 2023
A Relative Strength Rating upgrade for Vertex Pharmaceuticals shows improving technical performance. Will it continue?
Via
Investor's Business Daily
BioMarin's Growth Prospects Soar with Potential Voxzogo and Roctavian Launches, Analyst Raises Price Target
January 11, 2023
Via
Benzinga
Top Picks For 2023: Catalyst Pharmaceuticals
January 02, 2023
Catalyst Pharmaceuticals is a small-cap biopharma company focused on in-licensing, developing, and commercializing novel medicines to treat rare diseases. Let's take a closer look to see why it's a top...
Via
Talk Markets
12 Health Care Stocks Moving In Thursday's Pre-Market Session
December 01, 2022
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
December 01, 2022
Good morning! We're starting off Thursday with a breakdown of the biggest pre-market stock movers traders need to know about!
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
November 29, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Canceled AdCom, UniQure's Hemgenix Approval Show Positive Signs For BioMarin's Hemophilia Candidate
November 23, 2022
Via
Benzinga
The FDA Just Approved The Most Expensive Drug Ever — Sending UniQure Stock On A Warpath
November 23, 2022
And shares of its developer are on a warpath this week.
Via
Investor's Business Daily
Why Biomarin Pharmaceutical Stock Hit A New 52-Week High Today
November 23, 2022
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) shares are trading higher by 6.97% to $97.54 Wednesday morning after the company announced advancements in the FDA review of ROCTAVIAN for adults with severe...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.